Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 20 (9), 1239-1251, 2019-09
Elsevier BV